Literature DB >> 19706978

Clinical relevance of plasma homocysteine levels in Taiwanese patients with coronary artery disease.

Mei-ling Cheng1, Hung-yao Ho, Jui-fen Lin, Yo-cheng Chen, Err-cheng Chan, Daniel Tsun-yee Chiu.   

Abstract

Homocysteine (Hcy) has recently been considered as a risk factor for cardiovascular disease. Coronary artery disease (CAD) is the third most common cause of mortality in Taiwan. The objective of our present study is to delineate the relationship between the plasma Hcy level and CAD in Taiwanese using an improved enzymatic method. Blood samples were collected from 86 CAD patients, which include 38 patients with acute coronary syndrome (ACS) and 48 patients with stable CAD, and 89 controls. Plasma Hcy levels were measured by HPLC and enzymatic methods. Plasma Hcy levels were 8.27 +/- 1.74, 8.50 +/-1.88 and 11.76 +/- 4.58 muM in normal controls, patients with stable CAD and those with ACS, respectively. Plasma Hcy levels were elevated in the cohort of ACS patients, as compared with those of normal controls or patients with stable CAD. Within the CAD group, patients with the highest quartile Hcy level (10.18-23.73 muM) had a significantly higher odd ratio for ACS, as compared with those with the lowest quartile Hcy level after multivariate adjustment. Plasma Hcy concentration can be used as an independent risk factor of ACS, particularly for those with a history of CAD. Moreover, our improved enzymatic assay can be automated for large-scale screening of high-risk cohorts.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19706978     DOI: 10.1002/biof.5520340204

Source DB:  PubMed          Journal:  Biofactors        ISSN: 0951-6433            Impact factor:   6.113


  1 in total

1.  Impact of Homocysteine Level on Long-term Cardiovascular Outcomes in Patients after Coronary Artery Stenting.

Authors:  Jih-Kai Yeh; Chun-Chi Chen; Ming-Jer Hsieh; Ming-Lung Tsai; Chia-Hung Yang; Dong-Yi Chen; Shang-Hung Chang; Chao-Yung Wang; Cheng-Hung Lee; I-Chang Hsieh
Journal:  J Atheroscler Thromb       Date:  2016-11-01       Impact factor: 4.928

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.